Filtered By:
Source: Thrombosis Research
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Ex vivo reversal of the anticoagulant effects of edoxaban
This study evaluated the effect of two prohemostatic agents, recombinant factor VIIa (rFVIIa) and factor VIII inhibitor bypass activity (FEIBA), on the anticoagulatory effects of supratherapeutic concentrations of edoxaban in human whole blood ex vivo.
Source: Thrombosis Research - August 7, 2014 Category: Hematology Authors: Abdel-Baset Halim, Meyer M. Samama, Jeanne Mendell Source Type: research
Anti-apoptotic role of sonic hedgehog on blood platelets
Sonic hedgehog (Shh) is an essential morphogen involved in vertebrate organogenesis. Perturbation of Hh signaling is associated with pathological consequences like tumor formation and chronic lung fibrosis. Platelets are highly sensitive circulating blood cells responsible for hemostasis, while hyperactivity of these cells lead to morbidities like ischemic heart diseases and stroke. Despite being terminally differentiated cells with life span of 10-12 days, platelets have recently been shown to respond to Wnt ligand, another developmental signal similar to Shh.
Source: Thrombosis Research - September 25, 2014 Category: Hematology Authors: Sharda Kumari, Susheel N. Chaurasia, Kailash Kumar, Debabrata Dash Tags: Regular Article Source Type: research
Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - August 1, 2014 Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Tags: Regular Article Source Type: research
On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation
The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is currently not recommended, but measurements of dabigatran and/or its effect are desirable in certain situations. We studied dabigatran exposure and compared different tests for monitoring of dabigatran in a real-life cohort of AF patients.
Source: Thrombosis Research - July 6, 2014 Category: Hematology Authors: Mika Skeppholm, Paul Hjemdahl, Jovan P. Antovic, Josephine Muhrbeck, Jaak Eintrei, Yuko Rönquist-Nii, Anton Pohanka, Olof Beck, Rickard E. Malmström Tags: Regular Article Source Type: research
Mesenteric Venous Thrombosis and the need for a specialized Intestinal Stroke Center
Mesenteric Venous Thrombosis (MVT) is an uncommon cause of Acute Mesenteric Ischemia (AMI) (9-16% among four types of AMI), typically affecting the superior mesenteric vein and more rarely the inferior mesenteric vein [1–3].
Source: Thrombosis Research - November 6, 2014 Category: Hematology Authors: Raffaele Serra, Stefano de Franciscis Tags: Editorial Source Type: research
Normal Platelet Activation Profile in Patients with Peripheral Arterial Disease on Aspirin
Peripheral arterial disease (PAD) is a progressive vascular disease associated with a high risk of cardiovascular morbidity and death. Antithrombotic prevention is usually applied by prescribing the antiplatelet agent aspirin. However, in patients with PAD aspirin fails to provide protection against myocardial infarction and death, only reducing the risk of ischemic stroke. Platelets may play a role in disease development, but this has not been tested by proper mechanistic studies. In the present study, we performed a systematic evaluation of platelet reactivity in whole blood from patients with PAD using two high-throughput assays, i.e.
Source: Thrombosis Research - January 5, 2015 Category: Hematology Authors: Johanna P. van Geffen, Marie-Claire Kleinegris, Remco Verdoold, Constance C.F.M.J. Baaten, Judith M.E.M. Cosemans, Kenneth J. Clemetson, Hugo ten Cate, Mark Roest, Bas de Laat, Johan W.M. Heemskerk Tags: Regular article Source Type: research
The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment.
Source: Thrombosis Research - December 12, 2014 Category: Hematology Authors: A.T. Cohen, S. Imfeld, J. Markham, S. Granziera Tags: Review Article Source Type: research
Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis
: Atrial fibrillation (AF) is known as one of the independent risk factors for stroke and might significantly increase its risk. Nowadays, direct-acting oral anticoagulants (DOACs) have been developed and demonstrated a more promising option to warfarin, the conclusion for safety is heterogeneous in different studies. It indicates the importance of comprehensive comparison of safety between DOACs and warfarin.
Source: Thrombosis Research - April 10, 2015 Category: Hematology Authors: Fen Rong, Bin Jia, Pinxian Huang, Henry S. Lynn, Wei Zhang Tags: Regular Article Source Type: research
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model
Reperfusion injury after thrombolytic therapy can have adverse neurologic effects. The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke. However, basic investigations of this combination use remain inadequate. Here, we used an in vivo model to investigate the effects of edaravone on alteplase-induced thrombolysis.
Source: Thrombosis Research - April 13, 2015 Category: Hematology Authors: Tsutomu Yamashita, Takumi Sato, Kumi Sakamoto, Hiromitsu Ishii, Junichiro Yamamoto Tags: Regular article Source Type: research
Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation
The direct factor-Xa inhibitor apixaban is approved e.g. for the prevention of stroke in patients with atrial fibrillation (AF). Although routine monitoring of apixaban therapy is currently not recommended, selective monitoring could be useful to optimize efficacy and safety in certain clinical situations. We studied the exposure and effect of apixaban using different laboratory methods in a clinical setting with a well-defined cohort of AF patients.
Source: Thrombosis Research - April 29, 2015 Category: Hematology Authors: Mika Skeppholm, Fadiea Al-Aieshy, Maria Berndtsson, Faris Al-Khalili, Yuko Rönquist-Nii, Lisbeth Söderblom, Annika Y. Östlund, Anton Pohanka, Jovan Antovic, Rickard E. Malmström Tags: Regular Article Source Type: research
Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: Association with thrombin generation, endothelial injury and platelet activation
Formation of compact and poorly lysable fibrin clots have been demonstrated in patients following ischemic stroke. Recently, it has been shown that denser fibrin networks and impaired fibrinolysis occurs in subjects with permanent atrial fibrillation (AF). Fibrin clot phenotype in other types of AF remains to be established. We evaluated fibrin clot properties in paroxysmal (PAF) and persistent AF (PsAF).
Source: Thrombosis Research - May 28, 2015 Category: Hematology Authors: Leszek Drabik, Paweł Wołkow, Anetta Undas Source Type: research
A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event
β-antithrombin, the minor antithrombin glycoform in plasma, is probably the major thrombin inhibitor in vivo because of its high heparin affinity. The levels and variability of this glycoform in general population and its relevance in thromboembolic diseases is unknown since there is no specific method to measure this glycoform in clinical samples.
Source: Thrombosis Research - July 6, 2015 Category: Hematology Authors: M.E. de la Morena-Barrio, A. García, I. Martínez-Martínez, A. Miñano, J. Padilla, J. Navarro-Fernández, V. Roldán, S. Águila, J.A. Iniesta, J. Corral, V. Vicente Source Type: research
Self-Reported Adherence to Anticoagulation and Its Determinants Using the Morisky Medication Adherence Scale
Direct oral anticoagulants (DOACs) are used for treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF). Given the shorter half-life and lack of laboratory monitoring compared to vitamin-K antagonists (VKAs), adequate adherence to DOACs is important. Reported anticoagulation adherence is unclear in clinical practice.
Source: Thrombosis Research - July 13, 2015 Category: Hematology Authors: Lana A. Castellucci, Joseph Shaw, Katrien van der Salm, Petra Erkens, Gregoire Le Gal, William Petrcich, Marc Carrier Source Type: research
HAS-BLED score predicts risk of in-hospital major bleeding in patients with acute non-ST segment elevation myocardial infarction
In this study, we compared the HAS-BLED score with the Can Rapid Risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Catheterization and Urgent Intervention Triage strategY and the Harmonizing Outcomes with RevascularIZatiON and Stents in acute myocardial infarction (ACUITY-HORIZONS) bleeding risk scores for in-hospital major bleeding risk stratification in NSTEMI patients.
Source: Thrombosis Research - August 28, 2015 Category: Hematology Authors: Ming-Jer Hsieh, Chun-Chieh Wang, Chun-Chi Chen, Chun-Li Wang, Lung-Sheng Wu, I-Chang Hsieh Source Type: research
assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome
No study has examined how the relationship between polycystic ovary syndrome (PCOS) and atherosclerotic cardiovascular diseases (aCVD), of ischemic stroke (ISCH), acute myocardial infarction (AMI), and peripheral vascular disease (PAD), differ in the presence of venous thromboembolism (VTE).
Source: Thrombosis Research - October 13, 2015 Category: Hematology Authors: Ekwutosi M. Okoroh, Sheree L. Boulet, Mary G. George, W. Craig Hooper Tags: Full Length Article Source Type: research
